You just read:

myTomorrows Assumes Full Responsibility for European-Wide Promotion of Zevalin® (ibritumomab tiuxetan), the Radio-immunotherapy (RIT) Treatment for Follicular Non-Hodgkin Lymphoma Patients

News provided by

myTomorrows

12 Oct, 2016, 02:00 ET